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Adipose methylome integrative‑omic
analyses reveal genetic and dietary metabolic
health drivers and insulin resistance classifiers
Colette Christiansen1* , Max Tomlinson1,2, Melissa Eliot3, Emma Nilsson4, Ricardo Costeira1, Yujing Xia1,
Sergio Villicaña1, Olatz Mompeo1, Philippa Wells1, Juan Castillo‑Fernandez1, Louis Potier5, Marie‑Claude Vohl6,
Andre Tchernof7, Julia El‑Sayed Moustafa1, Cristina Menni1, Claire J. Steves1, Karl Kelsey3, Charlotte Ling4,
Elin Grundberg8, Kerrin S. Small1 and Jordana T. Bell1*

Abstract
Background: There is considerable evidence for the importance of the DNA methylome in metabolic health, for
example, a robust methylation signature has been associated with body mass index (BMI). However, visceral fat (VF)
mass accumulation is a greater risk factor for metabolic disease than BMI alone. In this study, we dissect the subcuta‑
neous adipose tissue (SAT) methylome signature relevant to metabolic health by focusing on VF as the major risk fac‑
tor of metabolic disease. We integrate results with genetic, blood methylation, SAT gene expression, blood metabo‑
lomic, dietary intake and metabolic phenotype data to assess and quantify genetic and environmental drivers of the
identified signals, as well as their potential functional roles.
Methods: Epigenome-wide association analyses were carried out to determine visceral fat mass-associated differen‑
tially methylated positions (VF-DMPs) in SAT samples from 538 TwinsUK participants. Validation and replication were
performed in 333 individuals from 3 independent cohorts. To assess functional impacts of the VF-DMPs, the associa‑
tion between VF and gene expression was determined at the genes annotated to the VF-DMPs and an association
analysis was carried out to determine whether methylation at the VF-DMPs is associated with gene expression. Fur‑
ther epigenetic analyses were carried out to compare methylation levels at the VF-DMPs as the response variables and
a range of different metabolic health phenotypes including android:gynoid fat ratio (AGR), lipids, blood metabolomic
profiles, insulin resistance, T2D and dietary intake variables. The results from all analyses were integrated to identify
signals that exhibit altered SAT function and have strong relevance to metabolic health.
Results: We identified 1181 CpG positions in 788 genes to be differentially methylated with VF (VF-DMPs) with
significant enrichment in the insulin signalling pathway. Follow-up cross-omic analysis of VF-DMPs integrating genet‑
ics, gene expression, metabolomics, diet, and metabolic traits highlighted VF-DMPs located in 9 genes with strong
relevance to metabolic disease mechanisms, with replication of signals in FASN, SREBF1, TAGLN2, PC and CFAP410. PC
methylation showed evidence for mediating effects of diet on VF. FASN DNA methylation exhibited putative causal
effects on VF that were also strongly associated with insulin resistance and methylation levels in FASN better classified
insulin resistance (AUC=0.91) than BMI or VF alone.
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Conclusions: Our findings help characterise the adiposity-associated methylation signature of SAT, with insights for
metabolic disease risk.
Keywords: DNA methylation, Visceral fat, Adiposity, Integrative omics

Background
Obesity is a global health concern, where the number of
obese adults worldwide has tripled since 1975 to 13% in
2016 [1] and is predicted to continue to rise [2]. Obesity
has a pronounced impact on an individual’s health, with
obese individuals more likely to suffer from type 2 diabetes (T2D), heart disease and cancer [3, 4], resulting in a
significant economic impact [5].
Despite evidence for a clear genetic component to
obesity, with GWAS studies identifying over 200 genetic
variants, these explain only 2–3% of variability in obesity
between individuals [6]. The dramatic rise in obesity in
recent years suggests involvement of environmental drivers. Epigenetic mechanisms are key regulators of gene
function that can respond to external stimuli. Multiple
epigenome-wide association studies of obesity have been
carried out, with the majority of studies in blood [7] and
relatively few investigating the adipose tissue methylome,
which is one of the most biologically relevant tissues for
metabolic health.
Several SAT methylome studies of obesity have been
carried out to date [8–11], each in up to 250 participants
across different ancestries and with different methylation technologies. A clear and strong adipose methylome
signature of obesity has emerged, with subsets of signals
also relating to glucose and insulin homeostasis, lipid
metabolism, and type 2 diabetes (T2D). Ronn et al. [9]
identified thousands of strong associations between BMI
and the adipose tissue methylome in approximately 200
Northern Europeans, but without adjustment for adipose
tissue cell heterogeneity. In contrast, Agha et al. [8] found
that after adjustment for adipose cell composition there
were no significant associations with BMI, but associations were observed with other aspects of adiposity such
as android:gynoid fat ratio (AGR) in 100 participants
of mixed ethnicity. Orozco et al. [10] identified adipose
methylation signals associated with one or more of 32
traits related to obesity and T2D in 200 Finnish men and
based on these results developed a T2D classifier. Most
recently, Sharma et al. [11] detected over a hundred adipose methylation signals related to BMI and measures
of insulin sensitivity in 230 African Americans. Furthermore, a clear genetic influence on the adipose methylome
has also been identified [12, 13], and GWAS signals for
BMI exhibit strong impacts on adipose tissue methylome variation [12]. These observations suggest that adipose tissue DNA methylation levels not only show major

alterations with obesity but may also in part mediate
some genetic risk effects in obesity.
However, the majority of adipose tissue methylome
studies of obesity to date focus on BMI, which can be
an imprecise measure of adiposity without distinction
between lean and fat mass. In contrast, estimates of visceral fat (VF) mass accumulation around the abdominal
organs have been shown to confer stronger risk for metabolic disease than BMI alone [14]. For example, VF was
associated with impaired fasting glucose [15], hypertension and metabolic syndrome [16], while general adiposity was not. Multiple studies have linked VF to impaired
insulin signalling and insulin resistance (IR) [17–19]. VF
is correlated with liver fat accumulation and is prone to
inflammation [17], both of which lead to reduced insulin
signalling functionality, although the precise underlying
molecular mechanisms are not fully characterised. Furthermore, methylome profiling of visceral adipose tissue
in 199 severely obese individuals has revealed hundreds
of differentially methylated signals related to circulating
lipid levels, with both tissue-specific and shared effects
[20].
Here we aimed to dissect subcutaneous adipose tissue methylome alterations relevant to metabolic health,
by focusing on visceral fat accumulation as the major
risk factor for metabolic disease. We characterised the
SAT DNA methylation signature associated with VF
after controlling for BMI in 538 twins from the TwinsUK cohort [21]. At the majority of identified signals,
DNA methylation levels were concordant across SAT
and visceral adipose tissue (VAT), with consistent levels
of gene expression across these two types of adipose tissue. We then conducted a multi-omic follow-up analysis
integrating our signals with genetic, blood epigenetic,
SAT gene expression, diet, plasma metabolomic variation, and a range of metabolic phenotypes to assess and
quantify genetic and environmental drivers of the identified signals, as well as their potential functional roles.
Replication of components of the analysis was pursued
in three independent datasets (104 individuals from the
LEAP cohort in the New England Family Study [8], 28
T2D cases and 28 controls from the Danish Twin Registry [22], and 199 severely obese individuals undergoing
bariatric surgery at the Quebec Heart and Lung institute
[20]). To consider how our results relate to the clinical
consequences of elevated VF, we showed that a subset
of the identified signals have strong associations with
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insulin resistance and can serve as potential predictors of
IR.

Methods
Cohort sample datasets

The primary dataset in this study included 538 White
British female twins (mean age 58.9±9.5 years; Table 1)
from the TwinsUK cohort [23] who were free from major
diseases including cancer, and for whom SAT biopsy
DNA methylation levels were profiled. Three subsets
of the 538 primary TwinsUK dataset were included in
downstream follow-up analyses where participants had
complete relevant data (including 397 of 538 for diet
analyses, 347 of 538 for metabolomic analyses, and 528
of 538 for lipid analyses). Details of data collection for
the diet, metabolomic and lipid data have been previously described [23] and are described further below (see
TwinsUK phenotype data). A second set of TwinsUK participants included 901 individuals (mean age 57.8±10.1
years 97% female; Table 1) for whom whole blood DNA
methylation was profiled. These data are described further below (see TwinsUK study participants). The final
TwinsUK dataset included in this study contained 720
participants from the TwinsUK cohort for whom adipose
gene expression profiles were available, and these data
were used in the analysis of the association between gene
expression and visceral fat described previously [24], and
below (see Gene expression profiles and analyses).
Validation and replication were carried out in three
independent cohort datasets that are described in more
detail below (see ‘Validation and replication’). For validation using AGR as a surrogate adiposity phenotype,
we analysed a dataset of 104 individuals from the LEAP
cohort in the New England Family Study, as previously described [8]. For replication of metabolic health
impacts, two further datasets were used. These included
Table 1 Discovery sample participant characteristics
Tissue type

Blood

SAT

Number

901

538

Smoker status

109(S)

54(S)

283(Ex)

196(Ex)

509(N)

288(N)

% Female

97%

100%
58.9±9.5

Age (years) ± SD

57.8±10.1

BMI (kg/m2)

26.7±4.9

Visceral fat (g)

3117±1383

3198±1441

Correlation between BMI and
visceral fat

0.87

0.90

26.8 ±4.9

AGR

n/a

0.96±0.16

VF/TPM

n/a

0.109±0.022

28 T2D cases and 28 controls from the Danish Twin Registry as previously described [22], and 199 severely obese
individuals undergoing bariatric surgery at the Quebec
Heart and Lung institute as previously described [20].
A complete analysis plan including datasets, sample
sizes and analysis carried out on each dataset can be
found in Additional file 1: Fig. S1.
TwinsUK study participants

The primary dataset of 538 participants consisted of
107 monozygotic (MZ) twin pairs and 163 dizygotic
(DZ) twin pairs from whom SAT biopsy samples were
obtained, as previously described [21]. Briefly, subcutaneous tissue was dissected from the abdomen, near the
umbilicus. Fat was immediately stored in liquid nitrogen,
after separation from the skin layer. The second set of 901
study participants consisted of 422 MZ twin pairs and
73 DZ twin pairs, and 222 individuals overlapped with
the set of 538 twins with SAT biopsies. Descriptions of
DNA extraction in blood samples and SAT have been
described previously [21, 25]. All study participants provided informed consent. Ethical approval was granted by
the National Research Ethics Service London-Westminster, the St Thomas’ Hospital Research Ethics Committee.
TwinsUK phenotype data

The individuals included in the study attended clinical
research visits during which phenotype data and biological samples were collected. During the visit height and
weight were measured, and dual-energy X-ray absorptiometry whole-body scans (DXA) were carried out.
The total grams of VF obtained from the trunk region
in the DXA data were used to quantify VF, as previously
described [26, 27]. Briefly, DXA scans were undertaken
with participants lying flat and straight, and the relevant
fat mass was estimated in grams from a cross section of
the whole body at L4–L5, the typical location of a CT
slice. The procedure for taking these measurements,
quality control and the calculation of VF has previously
been described [26, 27]. Only individuals with complete
information for height, weight and VF were used in the
analysis. DXA scans were also used to estimate AGR and
trunk fat mass (TFM).
Fasting insulin and glucose levels were obtained from
all 538 participants’ whole blood samples collected during the clinical visits. Insulin resistance (IR) and type 2
diabetes (T2D) status were assessed through both questionnaire data and based on blood glucose and insulin
levels. For an individual to be classified as insulin resistant, they had at least two normal fasting blood glucose
readings (below 7 mmol/L) accompanied by a fasting
insulin level > 50 pmol/L or over 9 μU/ml. Individuals
with only one instance meeting these thresholds were
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removed from the controls. This categorisation resulted
in 114 IR cases (HOMA-IR 3.5 ± 1.5) and 284 IR controls
(HOMA-IR 1.1 ± 0.5) in the SAT dataset.
An individual was categorised as a T2D case if either
there were two or more indicators of T2D or T2D medication was listed in regular medications taken. Indicators included fasting blood glucose levels greater than
7 mmol/L on any occasion and self-reporting of T2D
incidence. Altogether, the SAT dataset included 15 T2D
cases and 378 T2D controls.
Lipid data were available for 528 twins with SAT methylation profiles. Total cholesterol, HDL, LDL and triglycerides were measured in blood serum in mmol/L. Total
cholesterol, HDL and triglycerides were determined by
a colorimetric enzymatic method. HDL cholesterol was
determined after precipitation of larger particles (chylomicron, VLDL and LDL) by magnesium and dextran
sulfate. LDL levels were estimated by using the Friedewald equation. Checks were carried out to ensure the
date difference between the date of methylation measurement and lipid collection was within 5 years. Outliers
were excluded based on a boxplot of lipid measurements,
where data points that are located outside the whiskers
of the boxplot are excluded. This left 525 subjects in the
downstream analysis for HDL, 499 for triglycerides, 527
for total cholesterol and 521 for LDL.
Fasting serum circulating metabolomic profiles were
measured by Nightingale Health Ltd, formerly known as
Brainshake Ltd (Vantaa, Finland; https://nightingaleheal
th.com/services) [28]. Metabolomic profiles were determined using targeted NMR spectroscopy, as previously
described [28]. Metabolomic profiles were obtained for
12 metabolic traits, 143 metabolite concentrations, 80
lipid ratios, 3 lipoprotein sizes and a measure of albumin. Metabolomic data processing in the larger TwinsUK
cohort sample has been previously described [29], and
briefly traits were log-transformed and scaled to standard
deviation units. This component of the analysis focused
on 347 of the 538 twins, including only individuals who
had metabolomic profiles within 5 years of the SAT
biopsy.
SAT and blood cell composition estimates

SAT cell composition proportions were estimated based
on previously developed approaches using gene expression profiles with CIBERSORT [24]. The estimated
proportion of adipocytes, macrophages and micro-vascular endothelial cells were included as covariates in all
downstream analyses involving SAT. Blood cell subtype
proportions were estimated based on DNA methylation profiles, using established methods [30]. Blood cell
estimates were obtained for monocytes, granulocytes,
immune cells (Natural Killer (NK) cells, CD8 and CD4)
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and plasmablasts. As the resulting cell subtype proportions were correlated, downstream analysis models
included only monocytes, granulocytes, NK cells and
CD8 naïve cells.
TwinsUK DNA methylation profiles and analyses

DNA methylation profiles for both SAT and whole blood
in twins were generated using the Ilumina HumanMethylation 450kBeadChip array (450k array) [31]. DNA
methylation levels were determined using methylation beta-values, defined as the ratio of the methylated
bead signal to the sum of the unmethylated bead signal
plus the methylated bead signal plus 100 [32]. Methylation beta-values range between 0 at unmethylated CpG
sites and 1 at fully methylated CpG sites. Enmix [33] was
used for methylation data processing and quality control.
ENmix was first applied for background and dye bias correction quantile normalisation of signals, and estimation
of adjusted beta-values. Missing data was assigned for
CpG signals with detP > 0.000001 and Nbead < 3. Sample outliers were excluded as missing data using standard parameters. Minfi [34] was used to exclude samples
with median methylated and unmethylated signals
below 10.5. Cross-reactive probes and probes containing and >2 alignment mismatches were excluded. Altogether, 438,594 probes were included in the downstream
analysis.
Epigenome-wide association scans (EWAS) were
carried out for VF in SAT both with and without BMI
as a covariate. DNA methylation values for each CpG
site were normalised to N(0,1) prior to fitting linear
models. Mixed effect linear models were fitted (using
lme4 and LmerTest in R) [35] where methylation was
the response variable, and VF was the predictor and
fixed effect covariates were BMI, age, smoking status,
cell type proportion and methylation chip and position of the sample on the chip, random effects covariates were zygosity, family. Multiple testing adjustment
was performed using a Bonferroni adjusted threshold
of 5% (P = 1.14 × 10−7). Methylation effect sizes were
calculated using the same linear model, but without
normalising DNA methylation levels to N(0,1) prior to
data analysis, and the results were also compared to
the normalised analysis. The association between VF
and DNA methylation levels was also assessed over
larger genomic regions, to identify VF differentially
methylated region (VF-DMR) using DMRcate [36, 37].
VF-DMRs were identified after correction for multiple testing genome-wide, based on DMRcate Fisher
FDR 5%.
Epigenetic analyses were also carried out to relate
methylation levels at the 1181 VF-DMPs as the
response variables and a range of different metabolic
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health phenotypes including AGR, VF/TFM, lipids,
blood metabolomic profiles, insulin resistance and
T2D. Overlap between the VF-DMPs and methylation
association signals from each metabolic phenotype
were established using a P-value cut off based on a
Bonferroni multiple testing threshold (P = 4.2 × 10−5).
SAT epigenetic age analyses applied three different
epigenetic ageing calculators to estimate DNA methylation age acceleration for each individual, based on
DNAm GrimAge [38], DNAm PhenoAge [39] and Horvath methylation age [40]. Mixed effect linear models
were fitted (using lme4 and LmerTest in R), where the
DNA methylation age acceleration was the response
variable with predictor visceral fat. Fixed effect covariates included age, smoking status and cell type composition and mixed effects included zygosity and family.
The analysis was run with and without BMI as a fixed
effect covariate.
Genome annotation and pathway analysis

CpG annotation to genes and with respect to CpG
density was based on the 450k Illumina manifest.
Further genomic annotations were carried out taking into account data from the ENCODE project
[41] and ChromHMM categorisation [42]. This enabled an assessment of the enrichment or depletion
of the differentially methylated signals relative to all
tested methylation probes from the 450k array. The
number of VF-DMPs mapping to each annotation
category (e.g. insulators) was compared to the total
number of CpGs tested mapping to that category.
Fisher’s exact test was used to determine whether
differences were significant, with a P-value threshold of P < 0.05.
To explore functional annotations to biological
processes and molecular pathways, the genes that
VF-DMPs annotated to were analysed with the Ingenuity Pathway Analysis (QIAGEN Inc. https://w ww.
qiage  n bioi  n form  a tics .  c om/  p rodu  c ts/  i ngen  u ityp
athway-analysis) and GOmeth in missMethyl [43].
Using IPA, we assessed evidence for enrichment of
canonical pathways for the VF-DMP genes against
all genes applying Fisher’s exact test. We considered
IPA pathway results that surpassed a P-value threshold (P < 0.01). We also applied the GOmeth function
in the missMethyl Bioconductor package in R [43]. In
GOmeth, we tested the 1181 significant CpGs against
a background of all 438,594 CpGs included in the
downstream analysis for enrichment in KEGG pathways. GOmeth includes allowance in the enrichment
calculation for the number of probes per gene in the
background set.
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Tissue specificity

The SAT samples included in the study consisted of subcutaneous fat. Previously published datasets [44, 45]
were used to explore differences between subcutaneous
fat methylation and visceral fat methylation levels at the
VF-DMPs. Our first assessment [44] estimated the number of VF-DMPs that fell in genomic regions that showed
over 10% methylation differences between the SAT and
VAT [44]. Our second assessment explored how many
VF-DMPs were also previously identified by MacartneyCoxon et al. [45] to be differentially methylated after multiple testing adjustment between SAT and VAT.
To assess the level of tissue specificity across SAT and
blood samples, we analysed the VF-methylation associations at the 1181 VF-DMPs in the 901 whole blood twin
samples, with and without taking into account BMI. The
resulting P-values were used to estimate their π0, the
overall proportion of true null hypotheses in all tests
performed, using Bioconductor qvalue [46]. We then
quantified the proportion of significant results π1, or the
proportion of true positives, corresponding to π1 = 1 −
π0 [47]. For the 222 individuals for whom both blood and
SAT methylation data were available, pairwise adiposeblood methylation correlations were estimated at the VFDMPs to further assess the level of tissue specificity.
Gene expression profiles and analyses

RNA-seq data [48] were available for 720 individuals with
available genotype information (median age 60, age range
38–64, median BMI 25, BMI range 16–47), and these
included the 538 twins in the current study. RNA-seq
generation and pre-processing in the SAT samples have
been previously described [24]. In summary, STAR software v2.4.0.1 [49] was used to align reads to hg19. Samples were excluded if they had less than 10 million reads
sequenced to known genes. Samples were also excluded if
reads were not properly paired. Gene counts were transformed into trimmed mean of M-values (TMM)-adjusted
counts per million (CPMs) and inverse-normalised prior
to all downstream analyses. The expression dataset was
filtered to a minimum of 5 gene counts in 25% of the
subjects.
Two analyses were carried out to assess the functional
impacts of the 1181 VF-DMPs. Firstly, the association
between VF and gene expression was determined at the
788 genes using a mixed effect linear model. The model
applied gene expression level as the response variable
and VF as the predictor, with fixed effect covariates
smoking, BMI, age, insert size and GC content and random effects covariates primer index, date of sequencing
sample, processing batch, family and zygosity. Secondly,
an association analysis was carried out to determine
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whether methylation at the VF-DMPs is associated with
gene expression. A mixed effect linear model for the
538 individuals was constructed with gene expression as
the response variable and methylation as the predictor.
Fixed and random effect covariates were consistent with
the analysis above, but also included VF as a fixed effect
covariate (in addition to fixed effect covariates smoking,
BMI, age, insert size and GC content and random effects
covariates, primer index, date of sequencing sample processing batch, family and zygosity). The strength of association was determined using LmerTest [35], consistent
with the EWAS analysis.
To explore whether gene expression or methylation
was the likely driver of the VF associations, the association model between VF and gene expression above was
rerun for the subset of 538 individuals with both methylation and expression data available. Methylation was then
added to the model as a covariate and the significance
(P-value) of the association between gene expression
and VF was determined. The extent to which the P-value
attenuated was observed. This analysis was also repeated
starting with the significance of the association between
methylation and VF, adding gene expression to the model
and observing the extent to which the P-value attenuated.
Genetic data, heritability and QTL analyses

A twin-based heritability analysis was carried out to
estimate heritability of the 1181 VF-DMPs using ACE
modelling [50], which assumes that phenotypic variance
is the sum of additive genetic effects (A), common environmental effects (C) and unique environmental effects
(E). Genotypes were available for all 538 individuals in
the sample and were used for the identification of methylation Quantitative Trait Loci (meQTLs) and expression
Quantitative Trait Loci (eQTLs). Genotyping of the full
TwinsUK genetic dataset has been described previously
[51]. Briefly HumanHap300, HumanHap610Q, HumanHap1M Duo and HumanHap1.2M Duo 1M arrays were
used to genotype the sample. Following pre-phasing
using IMPUTE2 without a reference panel, the resulting
haplotypes were used to perform fast imputation from
1000 Genome phase1 dataset. Following imputation,
quality control measures included the exclusion of SNPs
which failed Hardy Weinberg equilibrium (P < 1e−6),
had a MAF < 0.01, had missingness of more than 5% or
had an info score < 0.8. Individuals with discordant sex
were removed. Outliers were also removed using PLINK
2.0 (unrelated participants) and GENESIS (related participants) where a deviation of more than 7 SD from the
mean was considered an outlier. The data was further
pruned for relatedness with participants with IBS > 0.125
(calculated using PLINK 2.0) removed.
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A meQTL analysis was performed to test for the association between genetic variation and DNA methylation levels at the 1181 VF-DMPs in SAT. SNPs that were
meQTLs were determined by fitting a linear model in
MatrixEQTL R package [52], where the corrected methylation beta-values were the response variables, and dosage of minor allele was the predictor. Covariates included
age, predicted smoking status, genetic principal components as fixed effects and family relatedness as a random
effect. Only cis meQTL SNPs were included, where the
cis interval was defined as ± 1 Mb from CpG site. A stringent cis meQTL P-value threshold was used to test for
significance (P = 1 × 10−5), as previously described [12],
and the most associated SNP per CpG site was reported
as the meQTL for the VF-DMP.
We assessed the overlap between the VF-DMP
meQTLs SNPs and previously identified GWAS signals
for VF from the GWAS catalog [53]. Altogether, all 71
recorded GWAS studies in the catalogue for VF (26) or
BMI-adjusted waist-to-hip ratio (45) were included. The
studies identified 360 and 3172 SNPs associated with VF
and BMI-adjusted waist-to-hip ratio respectively. VFDMP meQTLs SNPs were compared against this GWAS
combined set of 3532 SNPs to explore overlaps.
We further analysed the association between genotype
at the most significant SNP for each of the 203 meQTLs
and VF in our sample of 538 individuals. A mixed effect
linear model (lme4) was fitted for all 538 participants
with VF as the response variable, dosage of the minor
allele as predictor, and covariates included BMI, age,
smoking status as fixed effects and family and zygosity as
random effects. Due to the small sample size, 8 nominally
significant SNPs (P < 0.05) were used in the downstream
Mendelian randomisation analysis.
A ratio estimator approach was used for Mendelian
randomisation [54]. Here, the causal estimate was calculated as the effect size of the association between genotype and VF, divided by the effect size of the association
between genotype and methylation. The standard error of
the estimate was calculated using the delta method based
on Taylor expansion. Finally using the standard error, a
95% confidence interval was constructed around the
causal estimate. Where this interval did not include zero,
the causal estimate was deemed to be significant. The
assumptions for Mendelian randomisation were assessed,
and the assumption that the SNP (meQTL) is associated
with the risk factor (VF) is met by design. However, the
second and third assumptions are less clearly met, as
there could be additional unknown links between genotype and VF.
In addition to the meQTL analysis, a cis eQTL analysis
was also carried out for the 788 genes annotated to the
VF-DMPs in the larger sample of 720 individuals from
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the TwinsUK cohort with available gene expression data.
Genetic effects at SNPs for each gene in a cis-window (a
1-MB region around the transcription start site (TSS) of
each gene) were analysed. SNPs with a MAF <5% were
excluded. As described in Glastonbury et al. [24], the
analysis was performed on the inverse-rank-normalised
gene expression residuals corrected for family and zygosity and RNA extraction batch. The QTLtools package in
R [55] was used for the analysis, adjusting for BMI, genotyping chip and 40 PEER factors. For consistency with
meQTL results, cis eQTL significant threshold matched
that applied for cis meQTLs (P-value = 1 × 10−5). To
assess co-localisation of meQTLs and eQTLs, a simplified approach was taken, where a direct comparison was
made between meQTL SNPs and eQTL SNPs.
Diet data and analyses

Dietary information was available for 397 of the 538 participants with SAT methylation. The data were based on
the 131 item EPIC-Norfolk food frequency questionnaire
(FFQ [56]) where FFQ data processing in the larger TwinsUK sample has previously described [57]. Briefly, the 131
food items were combined to form 54 food groups, with
intake for each group estimated as the sum of all weekly
servings. Data quality control was performed based on
a comparison between the energy intake implied by the
FFQ and the participants’ estimated basal metabolic rate.
We analysed both nutrient intakes and overall diet quality estimated by diet scores. Nutrient intake variables
explored here included biotin, cholesterol, magnesium,
fibre, protein, total sugars, total trans fat, tryptophan and
vitamin E intakes, all of which were previously identified
to be associated with VF [26]. Overall diet quality measures included the Healthy Eating Index (HEI) [58], the
alternate Healthy Eating Index (aHEI) [59], the Dietary
Approaches to Stop Hypertension (DASH) score [60],
the Alternate Mediterranean Diet Score (aMED) [61],
the Dietary Quality Index International (DQI-I) [62] ],
Health Eating Index (HDI) score [63] and the Nordic Diet
Score [64].
Diet epigenetic analyses were carried out assessing the
association between methylation levels at the 1181 VFDPs as the response variables and selected dietary intake
variables including nutrient intakes previously associated
with VF (biotin, cholesterol, magnesium, fibre, protein,
sugars, trans fats, tryptophan, vitamin E; based on Le Roy
et al. [26]), and estimated diet scores (HEI, aHEI, DASH,
aMED, DQI-I, HDI, Nordic) as predictors. A consistent
linear model was used to assess the methylation-diet
associations with covariates including age, BMI, smoking status, cell composition, batch effects as fixed effects,
family and zygosity as random effects. To assess evidence
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for significant VF-DMP associations with dietary variables, we considered results that surpassed Bonferroni
multiple testing correction (P = 4.2 × 10−5).
To assess the mediation effect of methylation on the
impact of diet on VF, we carried out a mediation analysis using the mediation package in R [65]. Methylation
at CpGs identified to harbour differential methylation
effects for both VF and diet (VF/diet-DMPs) was used as
a mediator for the causal effect of the relevant diet variable on VF. Before undertaking a mediation analysis, the
association between VF and the dietary variables where
overlapping methylation associations were found (fibre,
magnesium, DASH score, Nordic score, DQI-I score)
was determined. A consistent linear mixed effect model
(lme4) was used with VF as response variable, the dietary
variable as predictor, and fixed effect covariates including
age, smoking, BMI, age, cell composition and batch, and
random effects covariates zygosity and family. All of the
dietary variables were significantly associated with VF at
P <0.05 (Additional file 2: Table S5).
The R mediation package uses a single mediator and
fibre, magnesium and DASH diet score all had more than
one associated VF/diet-DMP. For each of these dietary
variables, the CpG site with the most significant association with the diet variable was used as the mediator.
Outcome models were constructed using mixed effects
models (lme4) with the diet variable as the predictor
and fixed effect covariates smoking, age, BMI, cell composition, batch and random effect covariates family and
zygosity. Mediator models were constructed using the
same approach with an additional predictor including
DNA methylation levels at the relevant CpG site. For
each mediation analysis, we report the average causal
mediation effect (ACME), representing the average size
of the effect of a diet variable on VF that is mediated by
methylation. We also report the proportion of the effect
that is mediated. We then report the average direct effect
(ADE), where ADE represent the direct effect of the diet
variable on VF. If only ACME is significant, there is a full
mediation by methylation of the association between the
diet variable and VF. If both ADE and ACME are significant, methylation has a partial mediating effect.
Insulin resistance classifier

We tested whether insulin resistance status could be predicted using DNA methylation levels at the most significantly differentially methylated site associated with IR,
namely in FASN (cg11950105). The analyses were carried out in the IR data set of 397 people (114 cases, age
58.3±8.5, BMI 30.9±5.3; 284 controls, age 59.2±10.2,
BMI 24.8±3.6). Training datasets were created by selecting 60% of the full dataset at random. Test datasets
were created with the remaining 40% of the full dataset.
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Altogether, 20 random samples were selected creating 20 random training and test set combinations. For
each of the training datasets, a generalised linear model
was fitted with IR as the outcome and predictors including unadjusted DNA methylation levels and covariates
(age, sex, BMI and smoker status) using the R glm function. The sensitivity and specificity were assessed using
receiver operative curve (ROC), implemented using the
pROC package in R [66]. Given the strong relationship
between IR and BMI, we tested the performance of the
methylation classifier compared to the performance of
BMI alone. Additionally, we tested the performance of
visceral fat alone. We tested whether there was a statistically significant difference between the two models using
the ROC test function (pROC package). The test dataset
was then loaded into the derived model with outcomes
predicted using the R predict function and an average
AUC was determined.
Validation and replication

We pursed validation and replication of VF-DMPs and
their relevance to metabolic health in three independent
cohort samples (Additional file 2: Table S9).
We first sought to validate the 1181 VF-DMPs using
AGR as a surrogate central adiposity phenotype. We fit
linear models with AGR as predictor and DNA methylation levels at VF-DMPs as the response variable in
the data set from Agha et al. [8]. The analysis included
104 individuals from the New England Family Study, the
LEAP cohort (mean BMI 30.9 ± 7.03, mean age 47 ± 1.7,
48% male, mixed ancestry), described in detail previously [67]. SAT was collected from the upper outer quadrant of the buttock. DNA extraction and profiling, along
with determination of AGR through DXA scanning has
been previously described in detail [8]. For the validation
analysis, a linear regression model was fit with covariates
including age, sex, smoking status, BMI and batch effects.
The analysis was carried out with and without adjustment
for cell composition effects. The process for cell composition adjustment has previously been described [8] and is
based on the reference-free method [68] with latent variables representing mean methylation. The latent variable
dimension (i.e. number of cell types) was estimated to be
23, which in a sample of 104 may lead to potential overfitting and attenuation of effects. The primary results do
not include adjustment for cell composition, and in the
cell adjusted reference-free analysis, we observed that
51% (592) of tested VF-DMPs showed a consistent direction of methylation association with AGR in the LEAP
cohort participants, and 2% displayed nominally significant effects with no results significant after multiple testing adjustment.
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Second, we pursued replication of selected phenotype
associations observed with the 19 VF-DMPs in 9 genes,
which in our data showed significant associations with
a wide range of metabolically relevant phenotypes,
including insulin resistance, triglycerides, HDL and
amino acid metabolites. We sought replication in two
further cohort samples, a T2D case-control study from
Nilsson et al. [22] and a set of unrelated obese individuals from Allum et al. [20].
The Nilsson et al. [22] Scandinavian case-control
study dataset included 28 T2D cases (BMI 27.4±3.6,
mean age 74.5±4.2, 46% female) and 28 controls (BMI
27.0±3.6; mean age 74.3±4.3; 46% female) from the
Danish Twin Registry, described previously [22]. DNA
extraction, methylation profiling and data quality control has been described previously [22]. Briefly SAT
samples were extracted, frozen and stored at −80 °C.
DNA was later extracted using DNeasy Blood and Tissue kit (Qiagen) and profiled on the 450k array. Of the
19 VF-DMPs, 18 CpG sites in 9 genes were available for
replication testing. Relationships between T2D cases
and controls were determined using paired Wilcoxon
statistics and the resulting P-value compared with a
Bonferroni threshold P = 2.8 × 10−3.
The final replication sample from Allum et al. [20]
included 199 severely obese individuals (BMI > 40;
mean age 37.2±8.8; 60% female) undergoing bariatric
surgery at the Quebec Heart and Lung institute, Quebec City, Canada, for whom visceral adipose tissue
samples were collected. DNA extraction, methylation
profiling and data quality control have been described
previously [20]. Briefly participants fasted overnight
and underwent anaesthesia, and VAT samples were
obtained within 30 min of the surgery from the greater
omentum. In addition to the VAT samples, lipid levels
(total cholesterol, HDL cholesterol, triglycerides) were
measured in blood plasma using enzymatic assays.
Plasma low-density cholesterol levels were estimated
with Friedewald formula. In the analysis, lipid levels
not normally distributed were transformed to a log
scale. Methylation was profiled using Methyl C Capture
Sequencing (MCC-seq), a targeted bisulfite sequencing epigenome profiling approach targeting 79.6Mb
including 210,883 CpG sites from the 450k array as
previously described [69]. We assessed the association
between DNA methylation levels of specific targeted
CpGs detected using the MCC-seq approach and the
lipid levels using a generalised linear model fitted to a
binomial distribution weighted for sequence coverage
adjusted for age, sex, batch effects and BMI. Further
details on this modelling have been previously reported
[20]. If there was not an exact match to the target VFDMP 450k array CpG site, we considered all MCC-seq
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Epigenome-wide Analysis in Adipose Tissue
Visceral Fat controlling for BMI: 1,181 VF-DMPs
Genomic Annotations, Pathway Analysis, AGR Validation, Tissue specificity

Adipose Tissue Gene Expression

Genetics

Insulin Resistance
108 CpG

eQTL

eQTM
FASN

Causal Mediation
MR 6 CpG

Amino Acids

Lipids

Clinical Phenotypes

TG
564 CpG

Leucine
149 CpG

HDL/HDL size
187 CpG

Isoleucine
132 CpG

Heritability

meQTL

Diet

Metabolic Phenotype

FASN, SREBF1, TBC1D14, CHST11, ACSL1, TAGLN2,
CFAP410, PC, BAT2

Clinical Relevance
Classification of Insulin Resistance
FASN cg11950105

Dietary intake
15 CpG
Meditation
13 CpG

PC

Replication
FASN, SREBF1, TAGLN2,
CFAP410, PC

Fig. 1 Study design. Epigenome-wide analyses of visceral fat (VF) were performed in 538 SAT samples, identifying 1181 VF-DMPs. The 1181
VF-DMPs were subject to downstream analyses assessing functional relevance using genomic annotations, tissue specificity, validation using a
related phenotype android/gynoid ratio (AGR), and corresponding SAT gene expression changes related to VF. The VF-DMPs were then further
analysed for association with genetic and lifestyle factors. Lastly, the signals were exploring using deep metabolic profiling across metabolic
phenotypes, including lipid levels and metabolomic profiles, with replication. The resulting analyses were integrated to identify a set of replicated
signals in genes with strong relevance to metabolic health

signals within a 250-bp window around the target CpG
site, reporting the most associated signal. Of the 19 VFDMPs, there was an exact match for 11 CpG sites and
at least one signal in the 250-bp window for 7 others.

Results
We characterised the SAT methylome signature of adiposity and metabolic disease risk, with integrative crossomic follow-up and deep phenotype profiling (Fig. 1).
The primary analysis aimed to investigate the relationship
between SAT DNA methylation levels and VF. We sought
to relate these findings to clinical outcomes including
insulin resistance and T2D. The biological relevance of
the findings was further explored through a deeper metabolic analysis of over 100 phenotypes including levels of
lipids and amino acids. A detailed analysis plan is presented in Additional file 1: Fig. S1.
Differential methylome signature associated with VF

The association between VF, assessed using dual-energy
X-ray absorptiometry (DXA) whole-body scans, and
DNA methylation was explored in the primary dataset of
538 SAT samples from TwinsUK (Fig. 1, Table 1), using

linear regression models correcting a number of covariates (see ‘Methods’). An epigenome-wide association
analysis identified 1181 CpG sites (VF-DMPs) annotated
to 788 genes that were statistically differentially methylated with VF, controlling for BMI, cell composition and
further biological and technical covariates (see ‘Methods’), at a Bonferroni multiple testing threshold (P =
1.14 × 10−7; Additional file 2: Table S1; Fig. 2a). Of the
1181 VF-DMPs, 660 (56%) were hypermethylated with
increasing VF, where VF-DMP effect sizes were estimated
by repeating the association analysis without methylation
normalisation. The effect sizes ranged in absolute value
from less than 1% to up to 5% change in the unadjusted
level of DNA methylation per kg of visceral fat, with a
median of 1.6% methylation change per kg of visceral
fat. The largest effect size was observed at cg23654401
(VOPP1), where methylation values were on average 5%
lower per kg increase of visceral fat. The lowest P-value
signal was obtained in MAML3 (cg16218705; P = 2.4 ×
10−19), which was previously reported to be differentially
methylated with BMI in blood [7]. For reference, results
without adjustment for BMI and association with BMI
only are both shown in Additional file 2: Table S1.
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Fig. 2 Subcutaneous adipose tissue differential methylation signature of VF. a A Manhattan Plot of the associations between VF and DNA
methylation, taking into account BMI resulting from epigenome-wide association analysis (N = 538). The red line shows the multiple testing
threshold (P = 1.14 × 10−7), and the blue line shows a relaxed significant threshold (P = 1 × 10−5). b Enrichment and depletion of VF-DMPs
resulting from epigenome-wide association analysis (N = 538) across genomic annotations. Log Fold changes show the proportion of VF-DMPs
annotated to particular genomic annotations, compared to all CpGs tested in each annotation. The plots show only annotation categories with
significant enrichments and depletions. c Comparison between the discovery cohort (TwinsUK) (N = 538) and validation cohort (LEAP; N = 104)
showing effect size for the associations resulting from the regression analysis between AGR and methylation at VF-DMPs without adjustment for
cell composition in LEAP. d Significant positive association between PhenoAge acceleration and VF accumulation with a line of best fit shown in
red along with its R2 value (N = 538). e GTEx gene expression levels in whole blood, visceral fat and subcutaneous fat for the 9 genes identified
in the study following the omic integration showing shared expression levels in the two types of adipose tissue (SAT and VAT), but differences in
expression levels between adipose tissue and whole blood. TPM is transcripts per kilobase million, and the median expression levels are shown in
Additional file 2: Table S10

The genomic distribution of the SAT VF-DMPs
adjusted for BMI was explored across genomic annotations, including location with respect to gene body and
CpG density (Fig. 2b). Consistent with previous observations that CpG islands (CGI) are less dynamic in
response to exposures than surrounding regions [70], we
observed a significant depletion of VF-DMPs in CGI (4%
relative to 30% of probes, P = 9 × 10−111) and enrichment in CGI shores and shelves. The largest enrichment
of VF-DMPs was obtained in enhancers, as predicted by
ChromHMM (26% relative to 10% of probes tested, P =
3 × 10−55), showing clear links between accumulation of

VF and changes in the regulatory genomic signature of
SAT. This is consistent with previous investigations into
methylation differences in regulatory regions for cardio
metabolic traits [20].
Enrichment analyses explored biological pathways targeting the 1181 VF-DMPs and the 788 genes to which
VF-DMPs were annotated. Using Ingenuity Pathway
Analysis, we observed significant evidence for enrichment for 47 molecular pathways, which included many
signalling pathways affecting metabolic health and cancer
(Additional file 2: Table S2), and where the top pathway
was Insulin Signalling (P = 4 × 10−6). KEGG pathway
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enrichment using GOmeth [43] for the 1181 VF-DMPs
similarly identified significant enrichment for signals in
genes involved in insulin signalling (P = 1.9 × 10−3), as
well as glycolipid and fatty acid metabolism pathways.
We sought to validate the VF-DMPs by assessing
methylation associations with other adipose phenotypes
related to VFM, including VF/TFM and android:gynoid
ratio (AGR), which has previously been linked to alterations in the SAT methylome in participants from the
LEAP cohort [8]. We tested the association between
AGR and DNA methylation levels, and between VF/TFM
and DNA methylation levels, at the 1181 VF-DMPs after
adjustment for BMI in the 538 participants from TwinsUK. All except one (cg00372886) of the 1181 VF-DMPs
showed significant associations after multiple testing
with VF/TFM with the same direction of effect as that
observed for VF, and cg00372886 showed nominally
significant associations. All the 1181 VF-DMPs showed
significant associations after multiple testing adjustment
with AGR (P = 4.2 × 10−5) with the same direction of
effect as that observed for VF. A subset of 1172 VF-DMPs
was then explored in the independent dataset of 104
younger male and female participants of mixed ethnicity from the LEAP cohort within the New England Family Study (mean BMI 30.9 ± 7.03, mean age 47 ± 1.7, 48%
male), described in detail elsewhere [8]. We observed
that 92% (1073 of 1172) of tested VF-DMPs showed a
consistent direction of methylation association with AGR
in the LEAP cohort participants (Fig. 2c), with 21% (220
of 1172) displaying nominally significant effects, with 9
sites significant after multiple testing correction (P = 4.2
× 10−5).
Two follow-up analyses explored the VF associated
methylation signature, first, over larger genomic regions,
and second, by minimising effects of genetic variation.
First, we assessed the association between VF and DNA
methylation levels over larger genomic regions, aiming to
identify VF differentially methylated regions (VF-DMR)
using DMRcate. Many VF-DMRs were identified after
correction for multiple testing genome-wide, including
cases where peak VF-DMRs overlapped peak VF-DMP
signals such as in the FASN and SREBF1 genes (Additional file 2: Table S11). Second, to minimise differential
methylation effects attributed to genetic variation, we
also carried out DNA methylation analyses in a sample subset of MZ twins with discordant VF levels, such
that differences in twin VF levels exceeded 1sd of the VF
distribution in our sample. MZ twins have very similar
genetic variation profiles and are matched for age and sex
effects. Altogether, only 7 MZ twin pairs showed discordant VF levels in our sample, and DNA methylation analyses within this subset alone identified both genome-wide
and nominally significant MZ-specific signals (Additional
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file 3), including at sites identified from the main analyses, for example, for cg03498175 annotated to ACSL1 (P
= 7.8 × 10−7), cg11950105 annotated to FASN (P =1.8 ×
10−5) and cg23875758 annotated to SREBF1 (P = 3.4 ×
10−5).
DNA methylation variation has been widely used to
provide estimates of biological ageing measures across
tissues, ages and species. We explored whether the accumulation of VF has an impact on biological ageing in
SAT, by testing the association between three epigenetic
ageing measures and VF. Epigenetic ageing measures
included the estimated age acceleration rates for three
predictors of age, lifespan and healthspan (Epigenetic
Age Acceleration [40], GrimAgeAccel [38] and Levine’s
PhenoAgeAccel [39]). The original Horvath Epigenetic
Age accurately estimates chronological age and deviations from chronological age, while GrimAge and Levine’s PhenoAge have been proposed as different measures
of lifespan and healthspan. In analyses not adjusting for
BMI, all three epigenetic ageing measures in our SAT
sample showed significant associations with VF, where
the most significantly associated was PhenoAgeAccel (P
= 2 × 10−28; GrimAgeAccel P = 1 × 10−7, Epigenetic
Age Acceleration P = 6 × 10−3). After adjustment for
BMI, only PhenoAgeAccel remained significantly associated with VF (P = 2 × 10−6; Fig. 2d).
VF‑DMP tissue specificity

This study was undertaken in SAT and identification of
VF-DMPs took into account SAT cell composition variation. We sought to assess whether the 1181 VF-DMPs
showed methylation differences between the SAT and the
visceral adipose tissue (VAT) methylome in independent published datasets. In our first assessment, only 127
out of 1181 VF-DMPs (10.8%) fell in genomic regions
that showed over 10% methylation differences between
the SAT and VAT methylomes in an independent dataset of three SAT and VAT samples [44]. Our second
comparison focused on SAT and VAT methylomes of 15
obese individuals [45], and only 5 of the 1181 VF-DMPs
showed significant differences between tissue types. The
results suggest that the majority of VF-DMPs in our SAT
sample have similar DNA methylation profiles across
VAT and SAT. In line with these methylation results,
gene expression profiles from the Genotype-Tissue
Expression (GTEx) resource were also highly consistent
between SAT and VAT at VF-DMP genes, but the majority showed differences across SAT and whole blood samples (Fig. 2e, Additional file 1: Fig. S5, Additional file 2:
Table S10). These findings provide a strong argument
that the SAT-DMPs identified are reflective of VAT.
Tissue specificity of VF-DMPs was also explored
between SAT and whole blood, in both the secondary
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TwinsUK dataset of 901 twins with blood methylation
profiles and in a subset of 222 twins with both SAT and
blood methylation profiles. Using the subset of 222 twins,
we assessed the correlation between SAT and blood DNA
methylation at the 1181 VF-DMPs. The majority of VFDMPs (888, 75%) show very low correlation between
blood and SAT methylation levels (−0.1<r<0.1), with
only 2 sites reaching a correlation greater than 0.5 (Additional file 1: Fig. S2). We next assessed the association
between whole blood DNA methylation and VF using
the 901 whole blood samples. Of the 1181 VF-DMPs
and after adjustment for BMI, there were no significant
associations between blood methylation and VF (π0 = 1).
Without adjustment for BMI, there was very weak evidence for blood methylation associations with BMI (π1
= 0.07), where 102 VF-DMPs showed nominally significant associations and no sites reached significance after
multiple testing (P = 4 × 10−5). This suggests that the
observed modest effects in blood are likely due to effects
of BMI rather than specific impacts of VF accounting for
BMI. These results provide evidence that the 1181 SAT
VF-DMPs are predominantly not found in whole blood,
and therefore may be adipose-specific or specific to the
mesenchymal cell lineage.
Subsets of VF‑DMPs exhibit corresponding gene
expression changes with VF

To characterize the functional signature of the SAT
VF methylome signals, we explored SAT gene expression profiles at the 788 genes annotated to VF-DMP.
We compared SAT DNA methylation and gene expression levels in the primary dataset of 538 twins, seeking
to identify expression quantitative trait methylation signals (eQTMs). DNA methylation and expression levels
were regressed at 848 CpG-gene pairs in cis, comprising 807 CpGs annotated to 717 genes after expression
quality control assessments. Significant associations
were observed at 109 CpG sites (13%) with 72 genes
(10%) after multiple testing correction (Additional file 2:
Table S3). The most significant correlation was obtained
between SAT DNA methylation at cg04029738 (in FASN)
and FASN expression levels (P = 2.5 × 10−23) where an
increase in methylation leads to a decrease in expression.
Methylation at a further 12 CpGs annotated to FASN also
significantly associated with its expression levels (Fig. 3).
Further significant methylation-expression associations
were observed at multiple CpG sites, including in the PC
(6 CpGs) and SREBF1 (5 CpGs) genes.
We next investigated the association between SAT gene
expression and VF at the 717 genes in the gene expression dataset of 720 TwinsUK participants. Pairwise gene
expression and VF associations identified 227 genes
(32%) to be significantly differentially expressed with
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VF after Bonferroni correction, with 415 genes (58%) at
nominal significance. Next, conditional analyses explored
whether methylation or expression was the likely driver
of the association with VF. In the subset of 538 participants for which expression and methylation data were
both available, 132 genes were significantly differentially
expressed with VF after Bonferroni correction, leading to
174 CpG-gene pairs. The majority of these associations
(66%) were no longer significant when methylation was
included as covariate in the VF-expression linear model
(Additional file 1: Fig. S3). In contrast, when the reverse
analysis was undertaken at the 1181 VF-DMPs, only 12%
of VF-DMPs were no longer significant if gene expression was included as a covariate in the VF-methylation
linear model. The observation that the majority of VFexpression associations attenuate after conditioning on
methylation suggests that methylation may likely be the
driver of the association with VF at the majority (66%) of
genomic regions that display both DNA methylation and
gene expression associations with VF.
Integrative genetic analyses highlight FASN

Obesity and metabolic health traits exhibit a clear genetic
component, and multiple studies have now shown that
a proportion of the human methylome is under strong
influence of genetic variation. We assessed if the differential methylation signature of VF may be influenced
by genetic variants, or DNA methylation quantitative
trait loci (meQTLs). Due to the study participants being
twins, we first applied twin-based heritability to explore
evidence for genetic effects underlying DNA methylation variation in the primary dataset of 538 TwinsUK
participants. Heritability results showed that 33% of the
SAT VF-DMPs had evidence for substantial influence of
additive genetic effects (A > 0.4). We then explored the
association between genetic variation in cis and DNA
methylation levels at the 1181 VF-DMPs in SAT, identifying 203 VF-DMP CpG sites (17%) with at least one
genome-wide significant cis meQTL SNP (P = 1 × 10−5;
Additional file 2: Table S4) in the primary dataset of
538 TwinsUK participants. We also carried out expression quantitative trait locus (eQTL) analysis in cis at the
717 genes in the larger dataset of 720 twins with SAT
expression profiles. Cis eQTLs were identified at 125
genes (17%) with at least one genome-wide significant
cis eQTL SNP (P = 1 × 10−5). Altogether, meQTLs were
also eQTLs at a little more than a quarter (54, 27%) of the
203 VF-DMPs under genetic influence (Additional file 2:
Table S4). For example, FASN had 211 eQTL SNPs that
were also meQTL SNPs for FASN VF-DMP cg06906087.
We then assessed whether meQTL SNPs for VF-DMPs
may also influence VF, integrating eQTL and eQTM findings. Our SAT meQTLs did not overlap with previously
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Positive Effect
Negative Effect
Fig. 3 Significant subcutaneous adipose tissue DNA methylation and gene expression associations at VF-DMPs. The strength of association
between DNA methylation and gene expression levels is shown from regression analysis (N = 538). There were 109 significantly associated
CpG-Gene pairs, where CpGs are shown in the outer ring with the length of the bars showing −log10(P-value) which ranges from 4.3 to 22.6.
Negatively associated pairs are in red, positively associated pairs are in blue. Gene names are shown inside the circle with the innermost ring
showing the chromosome number

identified GWAS signals for VF or waist hip ratio
adjusted for BMI [53]; therefore, we assessed the association between the 203 most associated meQTL SNPs and
VF in the 538 individuals in this study. No SNP-VF associations were significant after multiple testing. Nominally significant SNP-VF associations were obtained with
8 meQTL SNPs, which were then used as instrumental
variables in an exploratory Mendelian randomisation
analysis to investigate the putative direction of association between VF and methylation at the corresponding
VF-DMPs. At 6 VF-DMPs (in FASN, TNFSF14, LPCAT1,

FOXO1, CARS2), we observed nominally significant evidence for putative causal effects of DNA methylation on
VF (Additional file 2: Table S4). One of the 6 signals was
cg06906087 in the FASN gene, which has previously been
associated with insulin resistance [71]. Both FASN DNA
methylation and gene expression (P = 3.2 × 10−7) were
associated with VF in our study. In FASN, the instrumental variable SNP (rs34673303) exhibited both meQTL
and eQTL effects, and there was a corresponding significant eQTM methylation-expression association. Further examples included cg04828493 at the CARS2 gene,
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where the instrumental variable SNP was also both a
meQTL and eQTL, as well as signals in other genes relevant to metabolic health including cg01684175 in FOXO1
(involved in glucose regulation and adipogenesis) [72]
and cg22185977 in LPCAT1 (enzyme in the lipid-remodelling pathway) [73].
Methylation mediates diet effects in VF

DNA methylation levels can change in response to environmental stimuli and diet is a major risk factor for metabolic health. To explore impacts of diet on VF-DMPs, we
assessed DNA methylation associations at the 1181 VFDMPs with 17 diet variables previously associated with
VF accumulation [26] in the subset of 397 TwinsUK participants with diet data, which included specific nutrient
intakes and indices of overall diet quality (see ‘Methods’).
After multiple testing correction, 13 VF-DMPs (diet/VFDMPs) exhibited differential methylation with fibre and
magnesium intakes, and with three diet quality indices
(DASH, DQI-I and Nordic diet score) (Additional file 2:
Table S5). At the 13 DMPs, the direction of diet-DMP
effect was consistent with the VF-DMP effect, such that
a poorer diet score always corresponded to increasing VF
(Additional file 1: Fig. S4). The diet/VF-DMPs annotated
to 12 genes, with fibre, DASH and DQI-I all showing
differential methylation in PIK3R1 which is associated
with insulin resistance [74]. The remaining 11 genes
also included metabolically relevant genes such as PC
(involved in insulin secretion [75]), SLC2A2 (involved in
glucose transport, linked to T2D [76]), DGAT2 (involved
in TG synthesis [77]) and others.
To assess whether DNA methylation may mediate the
impact of diet on VF, we carried out mediation analyses focusing on diet variables that were significantly
associated with both VF and the 13 diet/VF-DMPs. As
expected, fibre and magnesium intake, and the three
diet quality indices (DASH, DQI-I and Nordic diet
score) all showed nominally significant associations with
VF in our data (Additional file 2: Table S5) with DQI-I
showing significance after multiple testing adjustment.
We then tested whether the diet-VF associations were
attenuated after inclusion of DNA methylation level as
a covariate in the model. Following inclusion of DNA
methylation as a covariate, all diet-VF associations were
attenuated (Fig. 4a, Additional file 2: Table S5). Associations between VF and fibre, DASH and Nordic diet
scores were all no longer nominally significant after
accounting for DNA methylation levels at diet-CpGs.
The association between magnesium and VF remained
nominally significant after including DNA methylation
levels at diet/VF-DMP cg19689330 (FARS2), with attenuation (original effect size = −1.7, standard error = 0.54,
P = 1 × 10−3 vs methylation conditional effect size −1.2,
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standard error = 0.53, P = 0.03), but not after including methylation at cg06142324 (HEPACAM; methylation conditional P = 0.1). The association between DQI-I
and VF remained nominally significant after including
DNA methylation levels at diet/VF-DMP cg26804336
(PIK3R1) and cg20793665 (intergenic) in the model,
although the strength of association was attenuated
(original effect size = −14.6, standard error = 4.2, P =
6 × 10−4 vs methylation conditional effect size = −8.7
(cg26804336) and −11.1 (cg20793665), standard error =
4 (cg26804336 and cg20793665), P = 0.04 (cg26804336)
and 0.008 (cg20793665)). A formal mediation analysis
was then carried out with DNA methylation level at the
most significantly associated CpG for each diet variable
as the mediator between diet and VF, using R mediate
[65]. We observed a full mediation effect of DNA methylation for VF associations with fibre, magnesium, DASH
and Nordic diet scores, where only the average causal
mediation effect (ACME) was significant (Fig. 4a, Additional file 2: Table S6). In total, methylation mediated 72%
(cg09710316 in SLC2A2, P < 0.001) of the effect of fibre
on VF, 47% (cg06142324 in HEPACAM, P < 0.001) of the
effect of magnesium on VF, 46% (cg12187358 in LAYN,
P = 0.004) of the effect of the DASH diet score and 60%
(cg04278105 in INF2, P < 0.001) of the effect of the Nordic Score on VF. Only partial mediation was observed for
the DQI-I diet score, where both ACME and the average direct effect (ADE) were significant (cg26804336 in
PIK3R1, P < 0.001).
Deep functional metabolic phenotype assessment
of VF‑DMPs

To explore potential chemical sequelae of the adiposityrelated alterations to the SAT methylome, we assessed
the association of SAT DNA methylation levels at the
VF-DMPs with a large panel of blood lipid levels, serum
metabolomic profiles and clinically relevant phenotypes
such as insulin resistance (IR) and type 2 diabetes (T2D)
in subsets of the 538 participants with relevant complete
data.
We first linked the VF SAT methylation signatures to
cardiometabolic disease risk, by relating the 1181 VFDMPs to circulating serum lipid levels. Methylation
associations with levels of triglycerides (TG), total cholesterol, high-density lipoprotein (HDL) and low-density
lipoprotein (LDL) were assessed in 528 twins, controlling
for BMI. Nearly half of the VF-DMPs (564) were significantly associated with TG allowing for multiple testing
adjustment with a consistent positive direction of effect
as for VF-DMPs, and nearly all (1125) were nominally
significant. Similarly, 10% of VF-DMPs (109) were significantly associated with HDL allowing for multiple testing
adjustment, with consistent opposite direction of effects
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cg09710316

cg26804336

cg12187358

P value without
methylation
P value with
methylation

Fig. 4 VF-DMPs link to diet. Impact of DNA methylation on the association between diet and visceral fat (N = 397). Left-hand side plots show the
proportion of the effect mediated by methylation for each diet variable from the mediation analysis, and right-hand side shows the change in
P-value when methylation is included in the association model from regression analysis. A vertical dotted line shows P = 0.05 (nominal significance).
Results are shown for diet variables with significant associations with VF-DMPs

as for VF-DMPs, and the majority (984) were nominally
significant. FASN harboured the most significant signals
for TG and HDL associations, and SREBF1 also included
top associated signals for TG.
To further investigate the blood metabolic footprint
of the VF-DMPs, we related DNA methylation levels at
VF-DMPs to 239 fasting plasma and serum metabolites
analysed using a nuclear magnetic resonance (NMR)
metabolomics platform (Nightingale Health Ltd [28]) in
a subset of 347 (of the 538) twins. The platform assays
lipids and lipoprotein subclass profiles, fatty acids, amino
acids, ketone bodies and glycolysis-related metabolites.
Methylation-metabolite associations taking into account
BMI identified significant associations in 71 (42%) lipoproteins and 2 (66%) lipoprotein sizes, 2 (22%) cholesterol
metabolites, 3 (22%) glycerides/phospholipids, 1 (33%)
apoliprotein, 5 (31%) fatty acid, 1 (20%) glycolysis-related

metabolite and 6 (67%) amino acids (Additional file 2:
Table S7). The majority of significant VF-DMPs metabolite associations were observed with leucine, isoleucine
and HDL-related metabolites (Fig. 5a). As expected, most
VF-DMPs exhibited negative associations with HDL, and
positive associations with VLDL-related metabolites,
in line with previously reported negative correlations
between HDL and VF [78]. Similarly, the majority of VFDMPs showed positive associations with isoleucine and
leucine, in line with previous reports of increased levels
of these amino acids with increased risk of T2D, including incident T2D [79].
Finally, we assessed if the 1181 VF-DMPs methylation profiles capture variation in clinically relevant
phenotypes, such as IR and T2D. Methylation associations between VF-DMPs and IR, controlling for BMI,
were tested in a subset of 397 (114 IR cases / 284 IR
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Fig. 5 Deep functional metabolic phenotype analysis results. a Heatmap showing significant metabolite associations and their effect size from the
regression analysis for the 19 VF-DMP CpGs in 9 genes identified in the multi-omic integration (N = 347). Only significant associations are shown,
with grey areas reflecting correlations which did not meet the multiple testing significance threshold. Effect sizes for significant associations range
from −0.33 to 0.36. b Nominally significant association results from regression analysis for IR (N = 397, 114 cases/284 controls), TG (N = 528), HDL
(N = 528) and Leucine (N = 347) with the DNA methylation levels in the 9 genes identified in the multi-omic integration shown in red, in each case
the gene containing the most significant result has been highlighted. c Replication results for subsets of the 19 VF-DMP CpGs tested by regression
with T2D status (N = 56) in the Nilsson et al. [22] dataset (left), and with TG (N = 199) in the Allum et al. [20] dataset (right)

controls) SAT samples. Altogether, 108 of the 1181 VFDMPs (9%) showed a strong association with IR (IR/
VF-DMPs) after multiple testing correction (P = 4.2
× 10−5), and the majority (822, 70%) showed nominal
associations with a consistent direction of effect. The
most significant IR-DMP was cg11950105 annotated to
FASN (P = 5 × 10−12), with a further 14 sites in FASN
also significantly associated with IR (Fig. 6a). In contrast to IR, our T2D sample was very small (15 T2D
cases / 378 T2D controls) because the majority of the
538 female subjects with SAT biopsies were free from
major disease. Correspondingly, we did not observe significant associations after multiple testing adjustment
between VF-DMPs and T2D although at the majority
of sites (840, 71%) the T2D-methylation effect matched
the direction of the VF-methylation effect. Altogether,
4% of VF-DMPs (48 signals) were nominally associated
with T2D with a consistent direction of association as
that observed for VF-DMPs.

Integrating the deep metabolic phenotype methylation association results, we assessed overlaps between
VF-DMPs that were also significantly associated with IR,
circulating lipids and lipid and amino acid metabolomic
signatures (Fig. 1, Fig. 5b). The results identified 19 VFDMPs that annotate to 9 genes including FASN, SREBF1,
TBC1D14, CHST11, ACSL1, TAGLN2, CFAP410, PC
and BAT2, which leave a clear blood metabolic footprint
and significantly associate with IR (Additional file 2:
Table S8).
We pursued replication of the link between DNA methylation levels at the 19 VF-DMPs and metabolic health
parameters in two independent cohort samples. The first
replication set consisted of SAT samples from unrelated
participants from the Danish Twin Registry, including 28 T2D cases (BMI 27.4±3.6, mean age 74.5±4.2,
46% female) and 28 controls (BMI 27.0±3.6; mean age
74.3±4.3; 46% female). Of the 19 VF-DMPs, 18 were
tested and all showed a consistent direction of association
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Fig. 6 DNA methylation levels in FASN have predictive value for insulin resistance. a Epigenetic association from regression between VF and
FASN DNA methylation (N = 538) displayed in a coMET plot [80], including VF-methylation association profiles (top panel) along with functional
annotation of the region (middle panel), and pattern of co-methylation at the 53 CpG sites in the 450k array annotated to FASN (bottom panel).
Broad ChromHMM regions are displayed using UCSC genome browser colour schemes. b ROC curves for insulin resistance based on unadjusted
(not normalised) DNA methylation levels at cg11950105 (FASN) and age, smoking, BMI, SAT cell composition and technical covariates (n = 397, 114
cases/284 controls)

with T2D (Fig. 5c) and were nominally significant (P <
0.05). Altogether, 5 signals (annotated to FASN, SREBF1,
TAGLN, PC) replicated after multiple testing correction
(P = 2.8 × 10−3). The second replication sample included
visceral adipose tissue samples from 199 severely obese
individuals of European ancestry (BMI > 40; mean age
37.2±8.8; 60% female) undergoing bariatric surgery, as
previously described [20]. Replication analyses assessed
the association between DNA methylation levels at the 19
VF-DMPs with circulating lipid levels of TG, HDL, LDL
and total cholesterol. Of the 19 VF-DMPs, 18 were tested
and 33–44% were nominally significant and matched
direction of the discovery VF-DMP effect (Fig. 5c). Altogether, 4 VF-DMPs (annotated to FASN and CFAP410)
replicated after multiple testing correction (P = 2.8 ×
10−3). In summary, replication of the VF-DMP DNA
methylation effects in metabolic health (T2D and circulating lipid levels) was obtained for VF-DMPs in 5 genes
including FASN, SREBF1, CFAP410, TAGLN and PC.
DNA methylation classifier of insulin resistance

Lastly, we investigated the extent to which DNA methylation levels could be used to classify insulin resistance.

There was insufficient data to carry out the same analysis
for T2D and no other clinical traits were considered in this
study. Given the strong relationship between DNA methylation in FASN and IR, we focussed on this gene only. We
assessed the performance of DNA methylation levels at
FASN as a classifier of IR and therefore risk of metabolic
disease in the primary dataset of TwinsUK participants.
Given the strong relationship between IR and BMI, we
assessed the performance of a classifier based on DNA
methylation levels and BMI together, compared to the predictive power of BMI alone. Methylation at cg11950105 in
FASN combined with BMI was a strong predictor of insulin resistance with an average AUC of 0.91 (Fig. 6b). The
predictive value of this model was significantly greater
than that for a prediction model including only BMI,
which had an average AUC of 0.86 (P-values over 20 random training and test set combinations ranged from 0.001
to 0.03) or VF, which had an average AUC of 0.85.

Discussion
In this study, we dissected the SAT methylation signature
of visceral fat accumulation, a major risk factor for metabolic health. Our approach identified 1181 CpG sites in
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788 genes to be differentially methylated in 538 discovery
participants—one of the largest SAT samples to date [21],
with validation and replication in 333 individuals from
3 independent adipose tissue samples. The vast majority
of signals were not found in whole blood, annotating to
genes strongly enriched for pathways relevant to metabolic health with the most significant result in the insulin
signalling pathway. The VF-DMP signals were also validated for association with multiple adiposity measures
in the discovery cohort and one replication cohort. We
further found that visceral fat accumulation was significantly associated with accelerated biological ageing of
SAT, which is one pathway through which VF may play a
role in insulin resistance and metabolic disease. We integrated our visceral fat-associated SAT methylome results
with genetic, blood methylation, adipose gene expression, blood metabolomic, diet and metabolic phenotype
data, to identify and replicate signals in 5 genes (in FASN,
SREBF1, TAGLN2, PC, CFAP410) that exhibit altered
SAT function and have strong relevance to metabolic
health. A subset of these methylation signals showed evidence for mediating effects of genetic variation and diet
on VF, including signals in FASN and PC, respectively.
Furthermore, FASN DNA methylation also exhibited
putative causal effects on VF that were also strongly associated with insulin resistance, such that methylation in
FASN was a better classifier of IR than BMI alone.
Overall, FASN had the strongest links to metabolic
health where a number of CpG sites were associated with
visceral fat, insulin resistance and metabolic signatures.
FASN encodes an enzyme which catalyses the synthesis
of palmitate, the most common saturated fatty acid found
in animals. In FASN, genetic variants affected both DNA
methylation and gene expression levels, which were also
in turn both associated with VF, with evidence for putative causal methylation effects on increasing VF. The
locations of differential methylation in FASN observed
in our female-only sample are consistent with the SAT
methylome associations with insulin resistance observed
by Orozco et al. [10] in males, providing evidence for sexshared effects of FASN on metabolic disease risk. Furthermore, SAT methylation levels in FASN were strongly
predictive of insulin resistance status, significantly more
so than BMI alone. Circulating FASN has been previously proposed as a biomarker for overnutrition-induced
insulin resistance [71]. Whilst FASN effects in our study
were only observed in SAT, and not blood, our findings
are in line with previous reports of higher expression of
FASN in adipose tissue linked to increased visceral fat
and impaired insulin sensitivity [81]. Our hypothesis is
that SAT DNA methylation levels of FASN likely reflect
its DNA methylation levels in VAT and potentially other
tissues such as liver, which we propose in turn impact
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its gene function in these metabolically relevant tissues, with downstream effects on metabolic health. The
results also support a recently reported negative association [82] between adipose tissue FASN expression and
serum levels of a novel family of endogenous lipids with
anti-diabetic and anti-inflammatory effects, palmitic acid
hydroxy stearic acids (PAHSAs) [83]. Our results confirm the key role of FASN in metabolic disease risk and
provide insights into how specific genetic variants in this
gene exhibit regulatory functional genomic effects that
contribute to metabolic health.
Beyond FASN, our integrative methylation analysis with
genetic and gene expression data also identified putative causal effects of methylation in TNFSF14, LPCAT1,
FOXO1, CARS2 on VF, and where CARS2 DNA methylation and gene expression were also both under genetic
control. These genes have all been shown to have important metabolic functions. TNFSF14 encodes an inflammatory cytokine and enhanced levels of this cytokine are
associated with T2D [84]. Mouse studies have also shown
that deficiency in TNFSF14 improves liver glucose tolerance and reduces liver inflammation and non-alcohol
fatty liver [85]. LPCAT1 encodes an enzyme in the lipidremodelling pathway [73] and knockdown LPCAT1 mice
have greater cytotoxicity due to excess polyunsaturated
fatty acids [86]. FOXO1 encodes a transcription factor in
the insulin signalling pathway, regulating gluconeogenesis
and glycolysis. Inhibition of FOXO1 in fat cells has been
shown to mimic the impact of T2D and induce an insulin-resistant state [87]. Finally, whilst the role of CARS2
in metabolic health regulation is less clear, it is a critical mitochondrial gene with a role in protein synthesis,
charging tRNAs with amino acids. Whilst we observed
a putative causal link between SAT methylation and visceral fat, there are many routes via which these associations may take place. One possibility is that genetic and
environmental drivers of DNA methylation have similar
effects across multiple tissues, including VAT, pancreas
and others. Therefore, the methylation and gene expression changes observed in SAT could be surrogates for
signals from other tissues, for example VAT, which may
be the active mediators, including for potential dietary
impacts. Overall, a third of the signals in our study displayed gene expression associations with VF, showing that
not all of VF associated methylation signals have a corresponding association between gene function and VF. The
remaining signals may capture signatures of previously
accumulated ‘historic’ epigenomic variants, marking a
progression in central adiposity changes in the body.
Diet is a key risk factor for metabolic health; therefore,
we investigated how our visceral fat-associated methylation signals relate to dietary intakes previously associated with VF [26], revealing a subset of VF-DMPs also
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associated with fibre and magnesium nutrient intakes.
We also identified VF-DMPs associated with diet quality scores (DASH, DQI-I, Nordic), where in line with
expectation a poorer diet score always corresponded
to increasing VF. The signals are in 12 genes including in metabolically relevant genes such as PC, PIK3R1,
SCL2A2 and DGAT2. PC encodes pyruvate carboxylase, an enzyme with an important role in gluconeogenesis. Reduced levels of PC are found in the islets of T2D
patients and animal models have shown that blocking
this enzyme reduced insulin secretion [75], highlighting a role of this gene in metabolic health. Additionally,
PC has been suggested as a therapeutic target for insulin resistance [88]. PIK3R1 encodes an enzyme with
a direct role in insulin signalling and individuals with
mutations in PIK3R1 show severe insulin resistance [74].
For both PIK3R1 and SLC2A2 (which encodes a glucose
transporter) genetic polymorphisms are associated with
T2D [76]. Lastly DGAT2, is also an enzyme that catalyses the synthesis of triglycerides [77]. Methylation levels
at a subset of diet/VF-DMPs in SLC2A2 (cg09710316),
HEPACAM (cg06142324), INF2 (cg04278105) and LAYN
(cg12187358) mediated the association between diet
and VF, with up to 72% of dietary effect of VF mediated
through methylation levels. One exception was the association between DQI-I and VF at cg26804336 in PIK3R1;
however, this same CpG site showed a mediating effect
in the relationship between the DASH diet score and VF
and the relationship between fibre and VF. One of the
diet/VF-DMPs in the pyruvate carboxylase gene (PC,
cg01599099) also showed strong associations in subsequent analysis with multiple deep metabolic phenotypes.
Given these associations, a formal mediation analysis was
carried out and showed that methylation at cg01599099
(PC) mediated 35% of the association between the DASH
diet score and VF (Additional file 2: Table S6).
To assess the functional and clinical phenotypes
reflecting the adiposity-related alterations to the SAT
methylome, we related VF-DMPs with a large panel of
blood lipid levels, serum metabolomic profiles, insulin
resistance (IR) and type 2 diabetes (T2D). The results
identified marked strong associations between the 1181
VF-DMPs and IR. In addition to FASN, strong associations were seen for sites within SREBF. SREBF1 has consistently been reported to exhibit differential methylation
with T2D in blood [89]. However, SREBF1 was not found
to be associated with adiposity measures in other recent
adipose methylation studies [10, 11]. The metabolomic
profiling relationships further identified strong VFDMP associations with HDL and with leucine. There is
evidence that leucine supplementation may offer therapeutic possibilities in metabolic-related disorders [90].
Effects observed from dietary supplementation of leucine
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include improved lipid and glucose metabolism. Previous studies have found circulating levels of branched
chain amino acids including isoleucine and leucine to be
positively associated with measures of adiposity [91] and
T2D [92]. Integrating the results from all the metabolic
and clinical phenotypic analyses identified 19 VF-DMPs
that annotate to 9 genes, of which 5 achieved replication
(FASN, SREBF1, PC, TAGLN2 and CFAP410). Aside from
FASN, SREBF1 and PC, all of which have been previously
linked to metabolic health, previous work has shown that
TAGLN2 levels are increased in obese adipose tissue [93].
There are several limitations to the current study. Ideally, this study would be undertaken in visceral adipose
tissue (VAT). However, VAT samples are not typically
available for healthy research participants due to the invasive nature of the biopsy required. The VF-DMP signals
we obtained showed overall concordant DNA methylation levels across SAT and VAT samples, with consistent
gene expression changes. Although our discovery sample
is among the largest adipose tissue methylation datasets
profiled so far [21], a sample of 538 is nevertheless relatively modest for epigenetic analyses aiming to identify
moderate to small effects. The Mendelian randomisation
analysis included in the paper was limited by the sample
size and more robust conclusions would be drawn from
larger sample sizes. Our sample consisted of female-only
White British twins, and therefore, results may not translate to males and to other ethnicities, although a proportion of our findings were replicated in males and in mixed
sex cohort samples. The SAT samples were also predominantly from individuals who were not affected by major
disease [21], which may miss epigenetic changes relating
to obesity-related disease. Utilising a Bonferroni adjustment for multiple testing is a conservative approach as
it assumes that DNA methylation levels at CpG sites are
independent of each other, while multiple studies have
reported evidence for co-methylation [94]. Furthermore,
although the key clinical phenotypes were obtained at
time of adipose tissue biopsy in the discovery dataset, the
metabolomic profiles were obtained within up to 5 years
of time of biopsy sampling, where the time differences
may limit the interpretation of these results. A natural
extension to this work would be to carry out a longitudinal follow-up and to explore how baseline methylation
levels and their longitudinal trajectory relate to metabolic
disease incidence, to better disentangle cause from effect
at the identified changes.

Conclusions
In conclusion, the SAT methylome shows a distinct epigenetic signature associated with visceral fat after controlling for BMI. Integrating genetic, gene expression,

Christiansen et al. Genome Medicine

(2022) 14:75

metabolomics, diet and metabolic traits highlights five
genes after replication, with strong relevance to metabolic disease mechanisms. Our findings may help to
further understand the regulatory genomic pathways
underlying metabolic disease risk.
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